{"id":"W7098140935","doi":"","title":"Re: Hauschild A. Adjuvant interferon alfa for mela- noma: new evidence-based treatment recommenda-","year":2009,"lang":"en","type":"article","venue":"","topic":"HIV/AIDS oral health manifestations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Interferon alfa; Interferon; Adjuvant; Alpha interferon; Melanoma; Cancer; Disease; Clinical trial; Survival analysis","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00508435,0.001114969,0.002228606,0.003644444,0.00131075,0.002355877,0.002838125,0.009593731,0.01904502],"category_scores_gemma":[0.03705595,0.0007785053,0.00125629,0.002021711,0.002165541,0.003517589,0.0008356251,0.01755324,0.03728538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002541366,"about_ca_system_score_gemma":0.005499655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009973894,"about_ca_topic_score_gemma":0.02220422,"domain_scores_codex":[0.997498,0.0005817058,0.0003891342,0.0002445724,0.00117446,0.0001121585],"domain_scores_gemma":[0.9659162,0.01365243,0.002144698,0.00109078,0.01551944,0.001676573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004233785,0.000006042353,0.0001246847,0.0001176161,0.00001285782,0.0000841284,0.00001250598,0.00001401,0.00004837454,0.0004434263,0.9857328,0.01336135],"study_design_scores_gemma":[0.0001583822,0.00003656916,0.001842579,0.002846406,0.0001101153,0.000879624,0.0001540386,0.0002220566,0.0002717306,0.005037413,0.9883823,0.00005889782],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0002564639,0.07071693,0.0007588635,0.7975027,0.1162127,0.0000959453,0.0006863617,0.0001883623,0.01358173],"genre_scores_gemma":[0.004958395,0.07156719,0.002253707,0.7327335,0.1356191,0.0002626726,0.0006200173,0.0002268352,0.05175855],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.01904502,"threshold_uncertainty_score":0.06371194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1508898315036547,"score_gpt":0.4063009706913873,"score_spread":0.2554111391877325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}